Recent Updates — SGMT
Sagimet Biosciences filed an updated slide presentation for investors on October 22, 2026. The company reported a cash balance of $257.6 million as of June 30, 2026, which is expected to fund operations through mid-2029. This runway includes proceeds from a $115 million Series A equity offering completed in September 2026 and covers the readout of the denifanstat Phase 3 AURORA trial for moderate to severe acne, with first patient dosing occurring in October 2026 and top-line results expected in the second half of 2027. The presentation also highlighted that denifanstat met all primary and secondary endpoints in a prior Phase 3 trial conducted by partner Ascletis in China, where an NDA was accepted for review in December 2025. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase inhibitors for dermatological and metabolic diseases.
On September 30, 2026, Sagimet Biosciences Inc. entered into an underwriting agreement for a public offering of 8,750,010 shares of Series A common stock at $10.00 per share and pre-funded warrants to purchase up to 2,750,010 additional shares at $9.9999 per share. The transaction is expected to close on October 1, 2026, generating net proceeds of approximately $107.5 million after underwriting discounts. The company intends to use these funds to finance a Phase 3 clinical trial for denifanstat in acne, pre-launch activities, and the advancement of its topical formulation FASN inhibitor program to IND submission. Sagimet Biosciences Inc. operates in the biotechnology industry, focusing on the development of small molecule inhibitors for inflammatory diseases.
Sagimet Biosciences Inc. terminated its At-the-Market (ATM) equity offering program with Leerink Partners LLC effective September 30, 2026. The company also issued a press release announcing positive 52-week results from the Phase 3 ASC40-304 open-label extension clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd. in China. Denifanstat demonstrated sustained efficacy and safety over 52 weeks, supporting the upcoming U.S. AURORA Phase 3 trial expected to begin patient screening in October 2026. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors for metabolic and dermatological conditions.
On August 13, 2026, Sagimet Biosciences Inc. announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application and issued a "Study May Proceed" letter for the Phase 3 clinical trial of denifanstat in moderate to severe acne. This regulatory milestone allows the company to initiate pivotal testing for its fatty acid synthase inhibitor candidate. Sagimet Biosciences Inc. operates in the biotechnology industry, focusing on the development of small molecule therapeutics.
Sagimet Biosciences Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $14.0 million compared to $10.4 million in the prior year period. The company held $257.6 million in cash and marketable securities as of June 30, 2026, which management expects will fund operations through 2028, including data readout from its Phase 3 denifanstat trial. Sagimet announced plans to initiate a registrational Phase 3 clinical trial for denifanstat in moderate to severe acne patients in the United States during the second half of 2026. Additionally, the company confirmed that its first-in-human Phase 1 trial for the FASN inhibitor TVB-3567 is ongoing and aims to begin a Phase 2 acne trial before the end of 2026. Sagimet Biosciences Inc. operates in the clinical-stage biopharmaceutical industry, developing novel fatty acid synthase inhibitors for metabolic and dermatological diseases.
Sagimet Biosciences Inc. updated its investor presentation on July 20, 2026, highlighting clinical progress for its lead molecule, denifanstat. The company reported that denifanstat met all primary and secondary endpoints in a Phase 3 clinical trial for moderate to severe acne in China, where the NDA was accepted by the NMPA in December 2025. Sagimet plans to initiate a US-based Phase 3 clinical trial for denifanstat in the second half of 2026. Additionally, the company's follow-on FASN inhibitor, TVB-3567, began a Phase 1 clinical trial in June 2025. As of March 31, 2026, the company held $104.5 million in cash. Sagimet is a biotechnology company developing novel therapeutics for metabolic and dermatological diseases.